Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival

Annals of Oncology

Volumn 26, Issue 1, 2015, Pages 81-88

  Tobin, N P ^a   Harrell, J C ^b   Lovrot J ^a   Egyhazi Brage, S ^a   Stolt, Marianne Frostvik ^a   Carlsson, Lena ^c   Einbeigi, Zakaria ^d   Linderholm, Barbro ^a,d   Loman, Niklas ^e   Malmberg, Martin ^e   Walz, Thomas ^a,f   Ferno M ^g   Perou, C M ^b   Bergh, Jonas ^a   Hatschek, Thomas ^a   Lindström, Linda Sofie ^a,h   Hedenfalk, Ingrid ^a   Brandberg, Yvonne ^a   Carstensen, John ^a   Egyhazy, Suzanne ^a   Skoog, Lambert ^a   Hellström, Mats ^a   Maliniemi, Maarit ^a   Svensson, Helene ^a   Åström, Gunnar ^a   Bjöhle, Judith ^a   Lidbrink, Elisabet ^a   Rotstein, Sam ^a   Wallberg, Birgitta ^a   Carlsson, Per ^a   Malmström, Per ^a   Söderberg, Martin ^a   Lindh, Birgitta ^a   Sundqvist, Marie ^a   Malmberg, Lena ^a   more..

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Sundsvall General Hospital   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f LINKÖPING UNIVERSITY   (Sweden)

^g LUND UNIVERSITY   (Sweden)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biopsy at relapse; Breast cancer metastases; Gene expression; Gene modules; Metastasis characteristics; TEX randomized trial

Indexed keywords

BETA CATENIN; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAS PROTEIN; SOMATOMEDIN C; TRANSCRIPTION FACTOR E2F3; CASP3 PROTEIN, HUMAN; CASPASE 3; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADULT; APOPTOSIS; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST METASTASIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; TUMOR INVASION; UPREGULATION; BREAST; BREAST TUMOR; CLASSIFICATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR RECURRENCE;

APOPTOSIS; BETA CATENIN; BREAST; BREAST NEOPLASMS; CASPASE 3; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; TOR SERINE-THREONINE KINASES;

EID: 84922561724     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu498     Document Type: Article

References (18)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Davies C, Godwin J et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378(9793): 771-784.
2. Lindstrom LS, Karlsson E, Wilking UM et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012; 30(21): 2601-2608.
3. Niikura N, Liu J, Hayashi N et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2011; 30(6): 593-599.
4. Amir E, Miller N, Geddie W et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2011; 30(6): 587-592.
5. Thompson AM, Jordan LB, Quinlan P et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 2010; 12(6): R92.
6. Cardoso F, Fallowfield L, Costa A et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22(Suppl 6): vi25-vi30.
7. Wolff AC, Hammond MEH, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 2013; 31(31): 3997-4013.
8. Cardoso F, Costa A, Norton L et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012; 21(3): 242-252.
9. Hatschek T, Carlsson L, Einbeigi Z et al. Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial. Breast Cancer Res Treat 2012; 131(3): 939-947.
10. Bengtsson H, Simpson K, Bullard J, Hansen K. Aroma. Affymetrix: A Generic Framework in R for Analyzing Small to Very Large Affymetrix Data Sets in Bounded Memory. Berkeley: Department of Statistics, University Of California, Berkeley, 2008.
11. Benaglia T, Chauveau D, Hunter DR, Young DS. Mixtools: an R package for analyzing finite mixture models. J Stat Softw 2009; 32(6): 1-29.
12. Parker JS, Mullins M, Cheang MCU et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27(8): 1160-1167.
13. Desmedt C, Haibe-Kains B, Wirapati P et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008; 14(16): 5158-5165.
14. Ignatiadis M, Singhal SK, Desmedt C et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 2012; 30(16): 1996-2004.
15. Pawitan Y, Ploner A. OCplus: Operating Characteristics Plus Sample Size and Local fdr for Microarray Experiments R package version 1.40.0.
16. Shibue T, Weinberg RA. Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. Semin Cancer Biol 2011; 21(2): 99-106.
17. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011; 147(2): 275-292.
18. Cheang MCU, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. JNCI J Natl Cancer Inst 2009; 101(10): 736-750.